Literature DB >> 16171483

Factors associated with low immunity to rubella infection on antenatal screening.

Deshanie Sathanandan1, Leena Gupta, Bette Liu, Alison Rutherford, Jennifer Lane.   

Abstract

BACKGROUND: Rubella infection during the first trimester results in congenital rubella syndrome. There has been little recent published evidence identifying those at-risk of infection in the first trimester of pregnancy. This study examined the level of rubella immunity in pregnant women in a part of Sydney and risk factors for non-immunity.
METHODS: We looked at data on all confinements at two maternity hospitals in Sydney in the 2-year period between July 1999 and June 2001. Variables included in our data set included mother's country of birth, mother's date of birth, hospital status (public or private patient), parity, rubella status and postpartum rubella vaccination.
RESULTS: Of the 8096 confinements, the mother was documented as being non-immune to rubella in 567 cases (7%) of cases. Of the 567 confinements where rubella status was documented as non-immune, Asian-born women comprised of 65% (366) of non-immune women while 13% (73) were Australian-born. Country of birth remained a strong predictor of immunity, even after controlling for age, parity and hospital status. Maternal age > 35 years and nulliparity were also significant risk factors for non-immunity.
CONCLUSION: Programs targeting underimmunised populations for rubella vaccination should focus on overseas-born women, particularly those born in Asia, nulliparous women and also women > 35 years of age.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16171483     DOI: 10.1111/j.1479-828X.2005.00467.x

Source DB:  PubMed          Journal:  Aust N Z J Obstet Gynaecol        ISSN: 0004-8666            Impact factor:   2.100


  7 in total

1.  Prevalence of anti-rubella, anti-measles and anti-mumps IgG antibodies in neonates and pregnant women in Catalonia (Spain) in 2013: susceptibility to measles increased from 2003 to 2013.

Authors:  P Plans; F de Ory; M Campins; E Álvarez; T Payà; E Guisasola; C Compte; K Vellbé; C Sánchez; M J Lozano; I Aran; A Bonmatí; R Carreras; M Jané; L Cabero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-02-10       Impact factor: 3.267

2.  Rubella Immunity in Pregnant Native Taiwanese and Immigrants from Asian Countries.

Authors:  Yeong-Hwa Zen; Ching-Tang Shih; Wan-Ju Kung; Chien-Hung Lee; Ching-Chiang Lin
Journal:  Am J Trop Med Hyg       Date:  2016-11-28       Impact factor: 2.345

3.  Rubella seroepidemiology and catch-up immunization among pregnant women in Taiwan: comparison between women born in Taiwan and immigrants from six countries in Asia.

Authors:  Ching-Chiang Lin; Chun-Yuh Yang; Ching-Tang Shih; Bai-Hsiun Chen; Yeou-Lih Huang
Journal:  Am J Trop Med Hyg       Date:  2010-01       Impact factor: 2.345

4.  Improving access to immunisation for migrants and refugees: recommendations from a stakeholder workshop.

Authors:  Elizabeth Kpozehouen; Anita E Heywood; Margaret Kay; Mitchell Smith; Prakash Paudel; Mohamud Sheikh; C Raina MacIntyre
Journal:  Aust N Z J Public Health       Date:  2016-11-20       Impact factor: 2.939

5.  Seroprevalence of anti-rubella and anti-measles IgG antibodies in pregnant women in Shiraz, Southern Iran: outcomes of a nationwide measles-rubella mass vaccination campaign.

Authors:  Behnam Honarvar; Mohsen Moghadami; Afagh Moattari; Amir Emami; Neda Odoomi; Kamran Bagheri Lankarani
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

6.  A relatively high number of pregnant women in Kuwait remain susceptible to rubella: a need for an alternative vaccination policy.

Authors:  Nada Madi; Haya Al-Tawalah; Dina Abdul Khalik; Widad Al-Nakib
Journal:  Med Princ Pract       Date:  2014-01-15       Impact factor: 1.927

7.  Impact of the two-dose rubella vaccination regimen on incidence of rubella seronegativity in gravidae aged 25 years and younger.

Authors:  Shuk Yi Annie Hui; Daljit S Sahota; Terence T Lao
Journal:  PLoS One       Date:  2017-08-30       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.